Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Dec 22:5:18670.
doi: 10.1038/srep18670.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini, Sandro Barni, Salvatore Intagliata, Alfredo Falcone, Francesco Ferraù, Domenico Galetta, Luca Moscetti, Nicla La Verde, Toni Ibrahim, Fausto Petrelli, Enrico Vasile, Laura Ginocchi, Davide Ottaviani, Flavia Longo, Cinzia Ortega, Antonio Russo, Giuseppe Badalamenti, Elena Collovà, Gaetano Lanzetta, Giovanni Mansueto, Vincenzo Adamo, Filippo De Marinis, Maria Antonietta Satolli, Flavia Cantile, Andrea Mancuso, Francesca Maria Tanca  1 , Raffaele Addeo, Marco Russano, Michelle Sterpi, Francesco Pantano, Bruno Vincenzi, Giuseppe Tonini  2
Affiliations
Multicenter Study

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Daniele Santini et al. Sci Rep. .

Erratum in

  • Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.
    Santini D, Barni S, Intagliata S, Falcone A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli F, Vasile E, Ginocchi L, Ottaviani D, Longo F, Ortega C, Russo A, Badalamenti G, Collovà E, Lanzetta G, Mansueto G, Adamo V, De Marinis F, Satolli MA, Cantile F, Mancuso A, Tanca FM, Addeo R, Russano M, Sterpi M, Pantano F, Vincenzi B, Tonini G. Santini D, et al. Sci Rep. 2016 Apr 15;6:22205. doi: 10.1038/srep22205. Sci Rep. 2016. PMID: 27079142 Free PMC article. No abstract available.

Abstract

We conducted a large, multicenter, retrospective survey aimed to explore the impact of tumor bone involvement in Non-Small Cell Lung Cancer.Data on clinical-pathology, skeletal outcomes and bone-directed therapies for 661 deceased patients with evidence of bone metastasis were collected and statistically analyzed. Bone metastases were evident at diagnosis in 57.5% of patients. In the remaining cases median time to bone metastases appearance was 9 months. Biphosphonates were administered in 59.6% of patients. Skeletal-related events were experienced by 57.7% of patients; the most common was the need for radiotherapy. Median time to first skeletal-related event was 6 months. Median survival after bone metastases diagnosis was 9.5 months and after the first skeletal-related event was 7 months. We created a score based on four factors used to predict the overall survival from the diagnosis of bone metastases: age >65 years, non-adenocarcinoma histology, ECOG Performance Status >2, concomitant presence of visceral metastases at the bone metastases diagnosis. The presence of more than two of these factors is associated with a worse prognosis.This study demonstrates that patients affected by Non-Small Cell Lung Cancer with bone metastases represent a heterogeneous population in terms of risk of skeletal events and survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1. IV stage at diagnosis: patients with or without bone metastases.
Kaplan-Meier survival analysis.
Figure 2
Figure 2. Score to predict a different prognosis at diagnosis of bone metastases.
Kaplan-Meier survival analysis.
See this image and copyright information in PMC

References

    1. Siegel R., Ma J., Zou Z. & Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 64, 9–29 (2014) - PubMed
    1. Sandler A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355, 2542–50 (2006) - PubMed
    1. Johnson B. E. et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol ASCO Annual Meeting Abstracts. 31, 8019 (2013)
    1. Rosen L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. A randomised, Phase III, double blind, placebo-controlled trial. Cancer. 100, 2613–2621 (2004). - PubMed
    1. Price N., Belani C. P. & Jain V. K. Biphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer. 5, 267–269 (2004) - PubMed

Publication types